Japan Lymphedema Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), By Type (Secondary Lymphedema and Primary Lymphedema), and Japan Lymphedema Treatment Market Insights, Industry Trend, Forecasts to 2035

Japan Lymphedema Treatment Market Insights Forecasts to 2035

• The Japan Lymphedema Treatment Market Size Was Estimated at USD 16.41 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 10.44 % from 2025 to 2035
• The Japan Lymphedema Treatment Market Size is Expected to Reach USD 48.92 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan Lymphedema Treatment Market Size is anticipated to Reach USD 48.92 Million by 2035, Growing at a CAGR of 10.44 % from 2025 to 2035. The lymphedema treatment market in Japan is driven by various factors, including rising prevalence of lymphedema, rising awareness of post-treatment complications, rise in the geriatric population, and advancements in therapeutic interventions.

Market Overview

Lymphedema is a chronic condition characterized by the abnormal accumulation of lymphatic fluid, typically in the arms or legs, leading to swelling, discomfort, and reduced mobility. It frequently arises owing to injury or obstruction in the lymphatic system, and it is usually encountered as a secondary disease in patients receiving cancer therapies such as lymph node dissection or radiation therapy. The Japan lymphedema market refers to the production, distribution, and sale of therapies, devices, and services for managing lymphedema. The lymphedema treatment market includes various treatment types, such as compression therapy, surgery, drug therapy, laser therapy, and others. It covers treatment for both secondary lymphedema and primary lymphedema. A major contributor to the Japan lymphedema treatment market is the rising incidence of cancer in the country, particularly colorectal cancer, which is increasing at an annual rate of approximately 2.8 percent, according to the Japan Cancer Society. This surge in cancer cases has led to a higher prevalence of lymphedema, a common complication arising from cancer treatments such as surgery and radiation therapy. As cancer survival rates improve, a growing number of patients are living with chronic conditions like lymphedema, thereby increasing the demand for effective and advanced treatment options. Furthermore, professional bodies such as the Japanese Society of Clinical Oncology are actively involved in establishing guidelines and best practices for managing cancer-related lymphedema, highlighting the critical need for comprehensive treatment solutions. Rising preferences for non-surgical treatments are one of the key trends in this market. The ongoing research studies on lymphedema treatment are expected to influence the market growth. For instance, a 2023–2024 study in Japan found that Pneumatic Lymphatic Drainage, significantly reduced limb swelling in lymphedema patients with no common adverse effects, confirming its effectiveness and tolerability.

Report Coverage

This research report categorizes the market for the Japan lymphedema treatment market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan lymphedema treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan Lymphedema treatment market.

Driving Factors

The Japan lymphedema treatment market is experiencing significant growth due to rising awareness of lymphedema, especially among healthcare professionals, which is prompting early diagnosis and treatment options. Japan has one of the largest aging populations, and the aging population is more susceptible to chronic diseases such as cancer, which further leads to lymphedema, driving the demand for effective treatments. Additionally, technological advancements and rising awareness about lymphedema play an important role in market expansion.

Restraining Factors

One of the notable restraints is the high cost associated with advanced treatments and medical devices, which limits access for several patients, restraining the market expansion. Additionally, a complex approval process for new therapies and devices further slows down the market and innovation.

Market Segmentation

The Japan lymphedema treatment market share is classified into treatment type and application.   

• The compression therapy segment held the dominant share in 2024 and is expected to grow at a rapid CAGR during the forecast period.    

The Japan lymphedema treatment market is segmented by treatment type into compression therapy, surgery, drug therapy, laser therapy, and others. Among these, the compression therapy segment held the dominant share in 2024 and is anticipated to grow at a rapid CAGR during the forecast period. This segmental growth is attributed to its established reputation as the gold standard for lymphedema management and its non-invasive nature. Additionally, it is effective in reducing swelling and improving comfort.

• The secondary lymphedema segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Japan lymphedema treatment market is segmented by application into secondary lymphedema and primary lymphedema. Among these, the secondary lymphedema segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to its substantially higher prevalence, which is largely linked to cancer treatments such as lymph node dissection and radiation therapy.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan lymphedema treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Nipro Corporation
• Panasonic Healthcare
• Shimadzu Corporation
• Hitachi, Ltd.
• Canon, Inc
• Cardinal Health
• Sigvaris
• Jobst
• Smith & Nephew
• Juzo
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan lymphedema treatment market based on the below-mentioned segments:

Japan Lymphedema Treatment Market, By Treatment Type

• Compression Therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

Japan Lymphedema Treatment Market, By Type

• Secondary Lymphedema
• Primary Lymphedema